Thyroid Dysfunction and Lung Cancer Survival in China
Author Information
Author(s): Guo Ge, Jing Zihan, Dou Wenrui, Wang Guiqin, Dang JunJie, Li Yajie, Wang Ruqiong, Zhang Huan, Sun Jing, Shang Lihua
Primary Institution: Harbin Medical University Cancer Hospital
Hypothesis
Can immune-related thyroid dysfunction (irTD) serve as a prognostic marker for lung cancer patients undergoing immunotherapy?
Conclusion
Immune-related thyroid dysfunction (irTD) may be a positive prognostic factor for long-term survival in lung cancer patients receiving immunotherapy, particularly in those treated in later lines.
Supporting Evidence
- 42.7% of patients developed immune-related thyroid dysfunction (irTD).
- Patients with irTD had a median overall survival of 32.5 months compared to 22 months for those without.
- irTD was associated with longer overall survival in both NSCLC and SCLC patients receiving immunotherapy.
- Significant differences in inflammatory indices and thyroid-stimulating hormone levels were observed between irTD and non-irTD groups.
Takeaway
If you have thyroid problems while getting treatment for lung cancer, it might actually help you live longer, especially if you're getting the treatment later on.
Methodology
A retrospective analysis of lung cancer patients who received immune checkpoint inhibitors, assessing their thyroid function and survival outcomes.
Potential Biases
Potential biases due to retrospective design and selection criteria.
Limitations
The study may not account for all confounding variables and lacks data on TPOAb levels; it also does not include patients receiving neoadjuvant immunotherapy.
Participant Demographics
The study included 361 patients, predominantly male (68.1%), with a median age of 65 years or younger (62.6%).
Statistical Information
P-Value
0.005
Confidence Interval
0.49-0.88
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website